Biodesix Share Price (NASDAQ: BDSX)

$0.42

▲

0.02

(5%)

Live

Last updated on August 18, 2025 at 11:50 PM IST

$₹

Check the interactive Biodesix Stock chart to analyse performance

Biodesix stock performance

as on August 18, 2025 at 11:50 PM IST

Today's Low:$0.39
Today's High:$0.42
$0.42
7.64%
Downside
Day's Volatility :7.64%
Upside
0.0%
52 Weeks Low:$0.17
52 Weeks High:$2.04
$0.42
59.1%
Downside
52 Weeks Volatility :91.58%
Upside
79.41%

Biodesix Stock Returns

Period	Biodesix Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	31.66%	2.3%	0.0%
6 Months	-59.15%	-5.8%	0.0%
1 Year	-77.86%	-10.9%	0.0%
3 Years	-81.13%	2.8%	-11.6%

Biodesix Inc Key Stats

Check Biodesix key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.4
Open	$0.4
Today's High	$0.42
Today's Low	$0.3879
Market Capitalization	$58.1M
Today's Volume	$495.7K
52 Week High	$2.04
52 Week Low	$0.1718
Revenue TTM	$76.6M
EBITDA	$-28.1M
Earnings Per Share (EPS)	$-0.26
Profit Margin	-53.66%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-219.68%

Stock Returns calculator for Biodesix Stock including INR - Dollar returns

The Biodesix stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Biodesix investment value today

Current value as on today

₹27,537

Returns

₹72,463

(-72.46%)

Returns from Biodesix Stock

₹76,536 (-76.54%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Biodesix Stock

76%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Biodesix Stock from India on INDmoney has increased by 76% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Biodesix Inc

Name
Holdings %
Name
Holdings %
Telemark Asset Management, LLC
5.65%
Bryn Mawr Trust Company
4.16%
Birchview Capital, LP
3.91%
SILVERARC CAPITAL MANAGEMENT, LLC
2.80%
Monashee Investment Management LLC
2.76%
Vanguard Group Inc
2.59%

Analyst Recommendation on Biodesix Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Biodesix(by analysts ranked 0 to 5 stars)

Biodesix Share Price Target

What analysts predicted

Upside of 316.67%

Target:

$1.75

Current:

$0.42

Biodesix share price target is $1.75, a slight Upside of 316.67% compared to current price of $0.42 as per analysts' prediction.

Biodesix Stock Insights

Price Movement
In the last 1 month, BDSX stock has moved up by 24.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 17.95M → 20.01M (in $), with an average increase of 10.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -8.25M → -11.46M (in $), with an average decrease of 18.9% per quarter
BDSX vs IDXX (1 yr)
In the last 1 year, Idexx Laboratories, Inc. has given 32.2% return, outperforming this stock by 109.4%
BDSX vs IDXX (3 yr)
In the last 3 years, Idexx Laboratories, Inc. has given 73.7% return, outperforming this stock by 154.8%
Price to Sales
ForBDSX every $1 of sales, investors are willing to pay $0.7, whereas for Idexx Laboratories, Inc., the investors are paying $13.1 for every $1 of sales.

Biodesix Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$24.6M	↑ 20.16%
Net Income	$-30.7M	↑ 17.43%
Net Profit Margin	-125.15%	↑ 2.91%

	FY20	Y/Y Change
Revenue	$45.6M	↑ 85.55%
Net Income	$-31.4M	↑ 2.03%
Net Profit Margin	-68.81%	↑ 56.34%

	FY21	Y/Y Change
Revenue	$54.5M	↑ 19.64%
Net Income	$-43.2M	↑ 37.67%
Net Profit Margin	-79.18%	↓ 10.37%

	FY22	Y/Y Change
Revenue	$38.2M	↓ 29.89%
Net Income	$-65.4M	↑ 51.64%
Net Profit Margin	-171.27%	↓ 92.09%

	FY23	Y/Y Change
Revenue	$49.1M	↑ 28.46%
Net Income	$-52.1M	↓ 20.32%
Net Profit Margin	-106.23%	↑ 65.04%

	FY24	Y/Y Change
Revenue	$71.3M	↑ 45.3%
Net Income	$-42.9M	↓ 17.67%
Net Profit Margin	-60.19%	↑ 46.04%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$14.8M	↑ 1.02%
Net Income	$-13.6M	↑ 48.97%
Net Profit Margin	-91.87%	↓ 29.56%

	Q2 FY24	Q/Q Change
Revenue	$17.9M	↑ 20.97%
Net Income	$-10.8M	↓ 20.61%
Net Profit Margin	-60.3%	↑ 31.57%

	Q3 FY24	Q/Q Change
Revenue	$18.2M	↑ 1.26%
Net Income	$-10.3M	↓ 5.09%
Net Profit Margin	-56.51%	↑ 3.79%

	Q4 FY24	Q/Q Change
Revenue	$20.4M	↑ 12.55%
Net Income	$-8.3M	↓ 19.57%
Net Profit Margin	-40.39%	↑ 16.12%

	Q1 FY25	Q/Q Change
Revenue	$18.0M	↓ 12.1%
Net Income	$-11.1M	↑ 34.54%
Net Profit Margin	-61.82%	↓ 21.43%

	Q2 FY25	Q/Q Change
Revenue	$20.0M	↑ 11.47%
Net Income	$-11.5M	↑ 3.31%
Net Profit Margin	-57.29%	↑ 4.53%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$18.5M	↑ 15.3%

	FY20	Y/Y Change
Profit	$23.6M	↑ 27.5%

	FY21	Y/Y Change
Profit	$24.0M	↑ 1.82%

	FY22	Y/Y Change
Profit	$24.1M	↑ 0.29%

	FY23	Y/Y Change
Profit	$36.1M	↑ 49.96%

	FY24	Y/Y Change
Profit	$55.8M	↑ 54.53%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$11.6M	↑ 3.09%

	Q2 FY24	Q/Q Change
Profit	$14.0M	↑ 20.66%

	Q3 FY24	Q/Q Change
Profit	$14.0M	↓ 0.54%

	Q4 FY24	Q/Q Change
Profit	$16.1M	↑ 15.14%

	Q1 FY25	Q/Q Change
Profit	$14.3M	↓ 11.39%

	Q2 FY25	Q/Q Change
Profit	$16.0M	↑ 12.15%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-21.7M	↑ 22.91%
Investing Cash Flow	$-1.9M	↑ 203.4%
Financing Cash Flow	$23.0M	↑ 20.7%

	FY20	Y/Y Change
Operating Cash Flow	$-21.4M	↓ 1.66%
Investing Cash Flow	$-2.9M	↑ 56.36%
Financing Cash Flow	$81.1M	↑ 253.17%

	FY21	Y/Y Change
Operating Cash Flow	$-28.2M	↑ 32.09%
Investing Cash Flow	$-2.5M	↓ 12.98%
Financing Cash Flow	$1.3M	↓ 98.44%

	FY22	Y/Y Change
Operating Cash Flow	$-45.0M	↑ 59.35%
Investing Cash Flow	$-3.5M	↑ 38.75%
Financing Cash Flow	$58.9M	↑ 4565.77%

	FY23	Y/Y Change
Operating Cash Flow	$-22.9M	↓ 49.15%
Investing Cash Flow	$-23.1M	↑ 552.57%
Financing Cash Flow	$29.1M	↓ 50.53%

	FY24	Y/Y Change
Operating Cash Flow	$-48.6M	↑ 112.72%
Investing Cash Flow	$-3.4M	↓ 85.08%
Financing Cash Flow	$52.1M	↑ 78.69%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-15.3M	↑ 33.88%
Investing Cash Flow	$-273.0K	↓ 90.9%
Financing Cash Flow	$791.0K	↓ 96.36%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-18.6M	↑ 21.27%
Investing Cash Flow	$-2.0M	↑ 631.5%
Financing Cash Flow	$51.3M	↑ 6387.36%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-10.7M	↓ 42.6%
Investing Cash Flow	$-286.0K	↓ 85.68%
Financing Cash Flow	$144.0K	↓ 99.72%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-4.1M	↓ 61.62%
Investing Cash Flow	$-884.0K	↑ 209.09%
Financing Cash Flow	$-181.0K	↓ 225.69%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-8.6M	↑ 110.01%
Investing Cash Flow	$-137.0K	↓ 84.5%
Financing Cash Flow	$97.0K	↓ 153.59%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-6.6M	↓ 23.65%
Investing Cash Flow	$-95.0K	↓ 30.66%
Financing Cash Flow	$9.8M	↑ 9991.75%

Biodesix Technicals Summary

Sell

Neutral

Buy

Biodesix is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Biodesix Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biodesix Inc	13.23%	-59.15%	-77.86%	-81.13%	-96.91%
Agilent Technologies Inc.	6.39%	-11.83%	-15.17%	-13.38%	21.68%
Idexx Laboratories, Inc.	24.95%	44.93%	30.96%	74.14%	70.6%
Thermo Fisher Scientific, Inc.	20.76%	-6.52%	-19.52%	-16.91%	16.26%
Danaher Corp.	12.16%	3.13%	-22.24%	-27.87%	2.43%
Iqvia Holdings Inc.	20.21%	-1.07%	-21.4%	-20.05%	19.31%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biodesix Inc	NA	NA	NA	0.0	-2.2	-0.21	NA	0.01
Agilent Technologies Inc.	29.36	29.36	1.75	5.58	0.19	0.08	0.01	21.61
Idexx Laboratories, Inc.	54.06	54.06	4.87	12.6	0.65	0.23	NA	18.2
Thermo Fisher Scientific, Inc.	28.25	28.25	1.99	22.49	0.13	0.05	0.0	133.77
Danaher Corp.	44.88	44.88	2.11	7.77	0.07	0.04	0.01	73.1
Iqvia Holdings Inc.	27.69	27.69	1.1	11.87	0.2	0.05	NA	33.99

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biodesix Inc	Buy	$58.1M	-96.91%	NA	-53.66%
Agilent Technologies Inc.	Buy	$33.9B	21.68%	29.36	17.59%
Idexx Laboratories, Inc.	Buy	$52.1B	70.6%	54.06	24.41%
Thermo Fisher Scientific, Inc.	Buy	$184.7B	16.26%	28.25	15.24%
Danaher Corp.	Buy	$151.0B	2.43%	44.88	14.21%
Iqvia Holdings Inc.	Buy	$32.5B	19.31%	27.69	7.88%

About Biodesix Inc

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Organization	Biodesix
Employees	273
CEO	Mr. Scott Hutton
Industry	Health Services

Key Management of Biodesix Inc

Name	Title
Mr. Scott Hutton	President, CEO & Director
Ms. Robin Harper Cowie	CFO, Secretary & Treasurer
Mr. Kieran O'Kane	Chief Commercial Officer
Dr. Heinrich Röder	Founder & CTO
Ms. Jessica Olbricht	Senior Director of Human Resources
Dr. Gary Anthony Pestano Ph.D.	Chief Development Officer
Ms. Bobbi Coffin	Chief Growth Officer
Dr. James R. Jett M.D.	Co-Chief Medical Officer
Dr. Steven C. Springmeyer FCCP, M.D.	Co-Chief Medical Officer
Mr. Christopher Vazquez	VP & Controller

Important FAQs about investing in BDSX Stock from India :

What is Biodesix share price today?

Biodesix share price today is $0.42 as on August 18, 2025 at 11:50 PM IST. Biodesix share today touched a day high of $0.42 and a low of $0.39.

What is the 52 week high and 52 week low for Biodesix share?

Biodesix share touched a 52 week high of $2.04 and a 52 week low of $0.17. Biodesix stock price today, August 18, 2025 at 11:50 PM IST is trending at $0.42, lower by 79.41% versus the 52 week high.

How to invest in Biodesix Stock (BDSX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Biodesix on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biodesix Shares that will get you 3.5714 shares as per Biodesix share price of $0.42 per share as on August 18, 2025 at 11:50 PM IST.

What is the minimum amount required to buy Biodesix Stock (BDSX) from India?

Indian investors can start investing in Biodesix (BDSX) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Biodesix stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Biodesix share’s latest price of $0.42 as on August 18, 2025 at 11:50 PM IST, you will get 23.8095 shares of Biodesix. Learn more about fractional shares .

What are the returns that Biodesix has given to Indian investors in the last 5 years?

Biodesix stock has given -96.91% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?